Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)
The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units|
|Multiple Cities, Germany|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|
|Principal Investigator:||Trial Manager||For Germany, medinfoDEU@wyeth.com|